{"title":"对 \"芬氟拉明可减少伦诺克斯-加斯豪特综合征患者的癫痫发作频率,具有临床意义:开放标签扩展研究的中期分析 \"的更正。","authors":"","doi":"10.1111/epi.17999","DOIUrl":null,"url":null,"abstract":"<p>Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open-label extension study. <i>Epilepsia</i>. 2023;64(1):139–151. doi:10.1111/epi.17431</p><p>In Paragraph 2 on page 145 of Section 3.3 (“Effectiveness”) of the “Results” section, the following sentences contained data describing typical, non-ESC-confirmed drop seizures:</p><p>“In the overall treatment period, median percentage increase in days free of drop seizures was 41.6% compared to pretreatment baseline in the core RCT, with a median absolute change of 1.93 days per 28 days (range = −23.0 to 27.5 days; <i>p</i> < .0001). The longest interval between drop seizures increased from a median of 2.0 days (range = 1–17 days) to a median of 6.0 days (range = 1–365 days).”</p><p>The data ‘41.6%’, ‘1.93 days’, ‘27.5 days’, and ‘6.0 days’ needs to be updated for consistency with the data reported in the rest of the manuscript. The data in this paragraph should be updated to ESC-confirmed drop seizures, as shown below:</p><p>“In the overall treatment period, median percentage increase in days free of drop seizures was 44.6% compared to pretreatment baseline in the core RCT, with a median absolute change of 2.03 days per 28 days (range = −23.0 to 27.8 days; <i>p</i> < .0001). The longest interval between drop seizures increased from a median of 2.0 days (range = 1–17 days) to a median of 7.0 days (range = 1–365 days).”</p><p>The data ‘41.6%’ becomes ‘44.6%’, ‘1.93 days’ becomes ‘2.03 days’, ‘27.5 days’ becomes ‘27.8 days’, and ‘6.0 days’ becomes ‘7.0 days’.</p><p>In Table 2 on page 144 of Section 3.2 of the “Results”, the text “.3 to .5” should be “.3 to <.5”. In the next row, the text “>.5 to .7” should be “≥.5 to .7”.</p><p>In the first paragraph of Section 3.2 of the “Results” on page 144, line 5, the text “.3 - .5 mg/kg/day” should be “.3 - <.5 mg/kg/day”.</p><p>We confirm that these corrections do not change the interpretation of our results. We apologize for these errors.</p>","PeriodicalId":11768,"journal":{"name":"Epilepsia","volume":null,"pages":null},"PeriodicalIF":6.6000,"publicationDate":"2024-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/epi.17999","citationCount":"0","resultStr":"{\"title\":\"Correction to “Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open-label extension study”\",\"authors\":\"\",\"doi\":\"10.1111/epi.17999\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open-label extension study. <i>Epilepsia</i>. 2023;64(1):139–151. doi:10.1111/epi.17431</p><p>In Paragraph 2 on page 145 of Section 3.3 (“Effectiveness”) of the “Results” section, the following sentences contained data describing typical, non-ESC-confirmed drop seizures:</p><p>“In the overall treatment period, median percentage increase in days free of drop seizures was 41.6% compared to pretreatment baseline in the core RCT, with a median absolute change of 1.93 days per 28 days (range = −23.0 to 27.5 days; <i>p</i> < .0001). The longest interval between drop seizures increased from a median of 2.0 days (range = 1–17 days) to a median of 6.0 days (range = 1–365 days).”</p><p>The data ‘41.6%’, ‘1.93 days’, ‘27.5 days’, and ‘6.0 days’ needs to be updated for consistency with the data reported in the rest of the manuscript. The data in this paragraph should be updated to ESC-confirmed drop seizures, as shown below:</p><p>“In the overall treatment period, median percentage increase in days free of drop seizures was 44.6% compared to pretreatment baseline in the core RCT, with a median absolute change of 2.03 days per 28 days (range = −23.0 to 27.8 days; <i>p</i> < .0001). The longest interval between drop seizures increased from a median of 2.0 days (range = 1–17 days) to a median of 7.0 days (range = 1–365 days).”</p><p>The data ‘41.6%’ becomes ‘44.6%’, ‘1.93 days’ becomes ‘2.03 days’, ‘27.5 days’ becomes ‘27.8 days’, and ‘6.0 days’ becomes ‘7.0 days’.</p><p>In Table 2 on page 144 of Section 3.2 of the “Results”, the text “.3 to .5” should be “.3 to <.5”. In the next row, the text “>.5 to .7” should be “≥.5 to .7”.</p><p>In the first paragraph of Section 3.2 of the “Results” on page 144, line 5, the text “.3 - .5 mg/kg/day” should be “.3 - <.5 mg/kg/day”.</p><p>We confirm that these corrections do not change the interpretation of our results. We apologize for these errors.</p>\",\"PeriodicalId\":11768,\"journal\":{\"name\":\"Epilepsia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2024-05-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/epi.17999\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Epilepsia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/epi.17999\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epilepsia","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/epi.17999","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Correction to “Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open-label extension study”
Knupp KG, Scheffer IE, Ceulemans B, et al. Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open-label extension study. Epilepsia. 2023;64(1):139–151. doi:10.1111/epi.17431
In Paragraph 2 on page 145 of Section 3.3 (“Effectiveness”) of the “Results” section, the following sentences contained data describing typical, non-ESC-confirmed drop seizures:
“In the overall treatment period, median percentage increase in days free of drop seizures was 41.6% compared to pretreatment baseline in the core RCT, with a median absolute change of 1.93 days per 28 days (range = −23.0 to 27.5 days; p < .0001). The longest interval between drop seizures increased from a median of 2.0 days (range = 1–17 days) to a median of 6.0 days (range = 1–365 days).”
The data ‘41.6%’, ‘1.93 days’, ‘27.5 days’, and ‘6.0 days’ needs to be updated for consistency with the data reported in the rest of the manuscript. The data in this paragraph should be updated to ESC-confirmed drop seizures, as shown below:
“In the overall treatment period, median percentage increase in days free of drop seizures was 44.6% compared to pretreatment baseline in the core RCT, with a median absolute change of 2.03 days per 28 days (range = −23.0 to 27.8 days; p < .0001). The longest interval between drop seizures increased from a median of 2.0 days (range = 1–17 days) to a median of 7.0 days (range = 1–365 days).”
The data ‘41.6%’ becomes ‘44.6%’, ‘1.93 days’ becomes ‘2.03 days’, ‘27.5 days’ becomes ‘27.8 days’, and ‘6.0 days’ becomes ‘7.0 days’.
In Table 2 on page 144 of Section 3.2 of the “Results”, the text “.3 to .5” should be “.3 to <.5”. In the next row, the text “>.5 to .7” should be “≥.5 to .7”.
In the first paragraph of Section 3.2 of the “Results” on page 144, line 5, the text “.3 - .5 mg/kg/day” should be “.3 - <.5 mg/kg/day”.
We confirm that these corrections do not change the interpretation of our results. We apologize for these errors.
期刊介绍:
Epilepsia is the leading, authoritative source for innovative clinical and basic science research for all aspects of epilepsy and seizures. In addition, Epilepsia publishes critical reviews, opinion pieces, and guidelines that foster understanding and aim to improve the diagnosis and treatment of people with seizures and epilepsy.